← Leaderboards
William Stohl
University Of Southern California
$3,066,751
Attributed
$3,066,751
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $663.2K · FY2005–10$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$3,066,751 · 7
By mechanism
R01$2,036,446 · 2
M01$1,030,305 · 5
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Karen L Lindsay$3,850,131
- Robert C Seeger$12,536,093
- Stephen A. Stohlman$10,842,155
- Michael G Dube$1,076,796
- Michael D Kalos$995,280
Others in their field
Top investigators on “Systemic Lupus Erythematosus”
- Ignacio E. Sanz · University Of Rochester$57,737,718
- George C Tsokos · Beth Israel Deaconess Medical Center$37,219,358
- David Wofsy · University Of California, San Francisco$36,472,228
- Betty Diamond · Feinstein Institute For Medical Research$32,406,714
- John Barker Harley · Cincinnati Va Medical Center Research$30,355,689
- Patrick M Gaffney · University Of Minnesota Twin Cities$27,964,103
Research focus
Systemic Lupus ErythematosusLeukocyte Activation /TransformationClinical ResearchAntibody FormationHuman SubjectB LymphocyteCellular PathologyT LymphocyteCell Mediated CytotoxicityCellular ImmunityAutoimmune ProcessClinical TrialsB-LymphocytesBreedingBis(3-Bis(4-Chlorophenyl)Methyl-4-Dimethylaminophenyl)AmineAutoimmune DiseasesB-Cell DevelopmentBaseAdverse EventCell SurvivalClinical EfficacyAutomobile DrivingAutoimmunityCell Count
Grant awards (15)
The vital role of BAFF in the development of SLE$337,824
R01 · FY2010 · AR · contact PI
The vital role of BAFF in the development of SLE$341,237
R01 · FY2009 · AR · contact PI
The vital role of BAFF in the development of SLE$341,237
R01 · FY2008 · AR · contact PI
A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY$15,621
M01 · FY2008 · RR · contact PI
The vital role of BAFF in the development of SLE$348,201
R01 · FY2007 · AR · contact PI
A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY$12,598
M01 · FY2007 · RR · contact PI
The vital role of BAFF in the development of SLE$358,417
R01 · FY2006 · AR · contact PI
A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY$304,832
M01 · FY2006 · RR · contact PI
A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY$350,173
M01 · FY2005 · RR
T CELL CYTOLYTIC ACTIVITY IN SLE$0
M01 · FY2002 · RR
T CELL CYTOLYTIC ACTIVITY IN SLE$155,764
M01 · FY2001 · RR
T CELL CYTOLYTIC ACTIVITY IN SLE$0
M01 · FY2001 · RR
T CELL CYTOLYTIC ACTIVITY IN SLE$309,530
R01 · FY2000 · AR
T CELL CYTOLYTIC ACTIVITY IN SLE$155,764
M01 · FY2000 · RR
T CELL CYTOLYTIC ACTIVITY IN SLE$35,553
M01 · FY2000 · RR